AB203181

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8]

RabMAb
Recombinant
20ul selling size
What is this?

Be the first to review this product! Submit a review

(61 Publications)

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) is a rabbit monoclonal antibody detecting LRRK2 in Western Blot. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency
- Over 40 publications

View Alternative Names

PARK8, LRRK2, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

3 Images

PubMed

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Characterization of pS1292 LRRK2 antibody

Increasing amounts of HEK-293FT lysates transiently expressing WT LRRK2 (A) or S1292A LRRK2 (B) were analyzed by western blot and probed with the commercially available anti-pS1292 LRRK2 antibody (ab203181). The antibody showed minimal non-specific bands and linear detection in the range tested (b).

From Figure1a of Kluss et al.

All lanes:

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181)

Predicted band size: 286 kDa

false

Kluss et al NPJ Parkinsons Dis. 2018; 4: 13. Published online 2018 Apr 19. doi: 10.1038/s41531-018-0049-1. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/.

Supplier Data

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Blocking/Dilution buffer : 5% NFDM/TBST.

The image is provided by Dr. Paul Davies, University of Dundee, Dundee Scotland, UK.

G2019S mutation results in an increased LRRK2 auto-phosphorylation including S1292 (lane 3).

All lanes:

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg/mL

Lane 1:

LRRK2 mutant G2019S/S1292A transfected HEK293 lysate at 10 µg

Lane 2:

LRRK2 mutant G2019S transfected HEK293 inhibitor treated lysate at 10 µg

Lane 3:

LRRK2 mutant G2019S transfected HEK293 lysate at 10 µg

Lane 4:

LRRK2 mutant S1292A transfected HEK293 lysate at 10 µg

Lane 5:

LRRK2 wt transfected HEK293 inhibitor treated lysate at 10 µg

Lane 6:

LRRK2 wt transfected HEK293 lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP at 1/2500 dilution

Predicted band size: 286 kDa

Observed band size: 286 kDa

false

Supplier Data

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Blocking/Dilution buffer : 5% BSA/TBST.

The image is provided by Dr. Jeremy Nicols, Parkinson's Institute, Sunnyvale, CA, USA.

G2019S mutation results in an increased LRRK2 auto-phosphorylation including S1292 (lane 4).

Observed band size : 286 + 27 (GFP) = 313 kDa.

All lanes:

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg/mL

Lane 1:

GFP-LRRK2 wt transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose at 10 µg

Lane 2:

GFP-LRRK2 mutant D2017A transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose at 10 µg

Lane 3:

GFP-LRRK2 mutant S1292A/G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose at 10 µg

Lane 4:

GFP-LRRK2 mutant G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose at 10 µg

Secondary

All lanes:

Goat anti-rabbit (IRDye 800) at 1/10000 dilution

Predicted band size: 286 kDa

Observed band size: 313 kDa

false

Carrier free

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free
Carrier free

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

MJFR-19-7-8

Isotype

IgG

Carrier free

Reacts with

Human

Applications

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

style

left-column

Product details

What is this antibody validated in?
Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB) in Human samples.

What is the molecular weight of LRRK2?
Anti-LRRK2 (phospho S1292) [MJFR-19-7-8] (ab203181) specifically detects a band for LRRK2 (UniProt: Q5S007) at a molecular weight of 286kDa.

Trusted by the scientific community
Anti-LRRK2 (phospho S1292) [MJFR-19-7-8] (ab203181) was first used in a scientific publication in 2015 and has been cited over 40 times in peer-reviewed journals.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.

Other related products
We have a range of other formats of antibody clone [MJFR-19-7-8] also available for your convenience: ab203181, Carrier free - ab206035, Carrier free - ab256581

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein LRRK2 also known as leucine-rich repeat kinase 2 or dardarin is an enzyme with a molecular weight of approximately 286 kDa. It functions as a kinase meaning it adds phosphate groups to other proteins which affects their activity. LRRK2 is expressed in various tissues but it is highly abundant in the brain especially in regions such as the striatum and cortex. It has a significant role in cellular signaling processes due to its phosphorylation activity.

Biological function summary

LRRK2 interacts with cellular mechanisms by regulating cytoskeletal dynamics autophagy and vesicle trafficking. It is a part of a larger complex that includes other proteins involved in these processes. The kinase activity of LRRK2 plays an essential part in maintaining neuronal health and function. It influences the process of autophagy which is a way cells clean themselves by removing damaged components and recycling them.

Pathways

The action of LRRK2 is central to the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. In these pathways LRRK2 interacts with other proteins such as mTOR and RPS6KB1. It modulates cellular processes like growth proliferation and response to stressors. Its kinase activity affects the phosphorylation state of targets within the pathways hence influencing biological outcomes like survival and apoptosis.

LRRK2 mutations have a significant connection to Parkinson's disease and Crohn's disease. In Parkinson's disease mutated LRRK2 leads to abnormal protein aggregation linking to proteins such as alpha-synuclein. For Crohn's disease LRRK2 influences the immune response and intestinal inflammation. These connections highlight LRRK2's role in the pathogenesis and contribute to understanding these complex disorders.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed : 17114044, PubMed : 20949042, PubMed : 21850687, PubMed : 22012985, PubMed : 23395371, PubMed : 24687852, PubMed : 25201882, PubMed : 26014385, PubMed : 26824392, PubMed : 27830463, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB29, RAB35, and RAB43 (PubMed : 23395371, PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29127255, PubMed : 29212815, PubMed : 30398148, PubMed : 30635421, PubMed : 38127736). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed : 26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed : 26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed : 29125462, PubMed : 30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed : 23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed : 17114044). Plays a role in synaptic vesicle trafficking (PubMed : 24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed : 25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed : 22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed : 22012985). Phosphorylates PRDX3 (PubMed : 21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed : 28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed : 27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed : 26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed : 18230735, PubMed : 26824392, PubMed : 28720718, PubMed : 29125462, PubMed : 29212815). Recruited by RAB29/RAB7L1 to overloaded lysosomes where it phosphorylates and stabilizes RAB8A and RAB10 which promote lysosomal content release and suppress lysosomal enlargement through the EHBP1 and EHBP1L1 effector proteins (PubMed : 30209220, PubMed : 38227290).

See full target information LRRK2 phospho S1292

style

left-column

Publications (61)

Recent publications for all applications. Explore the full list and refine your search

The Journal of clinical investigation 135: PubMed41031878

2025

Targeting specific kinase substrates rescues increased colitis severity induced by the Crohn's disease-linked LRRK2-N2081D variant.

Applications

Unspecified application

Species

Unspecified reactive species

George R Heaton,Xingjian Li,Xianting Li,Xiaoting Zhou,Yuanxi Zhang,Duc Tung Vu,Marc Oeller,Ozge Karayel,Quyen Q Hoang,Meltem Ece Kars,Nitika Kamath,Minghui Wang,Leonid Tarassishin,Matthias Mann,Inga Peter,Zhenyu Yue

NPJ Parkinson's disease 11:61 PubMed40155632

2025

The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.

Applications

Unspecified application

Species

Unspecified reactive species

Lin-Hua Gan,Yi-Min Sun,Xin-Yue Zhou,Zhi-Yuan Qi,Feng-Tao Liu,Yi-Lin Tang,Wen-Bo Yu,Bao-Guo Xiao,Jian Wang,Jian-Jun Wu

BMC neuroscience 26:19 PubMed40038582

2025

Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.

Applications

Unspecified application

Species

Unspecified reactive species

Hoang Kieu Chi Ngo,Akriti Srivastava,Hoang Le,Samuel J Ayer,Grace F Crotty,Michael A Schwarzschild,Rachit Bakshi

Chemical science 16:3430-3439 PubMed39877816

2025

Functionally active modulators targeting the LRRK2 WD40 repeat domain identified by FRASE-bot in CACHE Challenge #1.

Applications

Unspecified application

Species

Unspecified reactive species

Akhila Mettu,Marta Glavatskikh,Xiaowen Wang,Antonio Jesús Lara Ordóñez,Fengling Li,Irene Chau,Suzanne Ackloo,Cheryl Arrowsmith,Albina Bolotokova,Pegah Ghiabi,Elisa Gibson,Levon Halabelian,Scott Houliston,Rachel J Harding,Ashley Hutchinson,Peter Loppnau,Sumera Perveen,Almagul Seitova,Hong Zeng,Matthieu Schapira,Jean-Marc Taymans,Dmitri Kireev

NeuroSci 5:301-314 PubMed39483283

2024

Therapeutic Effect of Extract on a Cell System Model for Parkinson's Disease.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Hwan Ho,Hyejung Kim,Daleum Nam,Mi Kyoung Seo,Sung Woo Park,Dong-Kyu Kim,Ilhong Son

NPJ Parkinson's disease 10:49 PubMed38429321

2024

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.

Applications

Unspecified application

Species

Unspecified reactive species

Nicholas Pena,Tara Richbourg,Claudia P Gonzalez-Hunt,Rui Qi,Paul Wren,Carrolee Barlow,Natalie F Shanks,Holly J Carlisle,Laurie H Sanders

Frontiers in molecular neuroscience 16:1269387 PubMed38169846

2024

PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation.

Applications

Unspecified application

Species

Unspecified reactive species

Lucia Iannotta,Marco Emanuele,Giulia Favetta,Giulia Tombesi,Laurine Vandewynckel,Antonio Jesús Lara Ordóñez,Jean-Michel Saliou,Matthieu Drouyer,William Sibran,Laura Civiero,R Jeremy Nichols,Panagiotis S Athanasopoulos,Arjan Kortholt,Marie-Christine Chartier-Harlin,Elisa Greggio,Jean-Marc Taymans

eLife 12: PubMed37874635

2023

Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson's disease-linked LRRK2 kinase.

Applications

Unspecified application

Species

Unspecified reactive species

Herschel S Dhekne,Francesca Tonelli,Wondwossen M Yeshaw,Claire Y Chiang,Charles Limouse,Ebsy Jaimon,Elena Purlyte,Dario R Alessi,Suzanne R Pfeffer

The Journal of biological chemistry 299:105192 PubMed37625589

2023

Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Alexandra Unapanta,Farbod Shavarebi,Jacob Porath,Yiyi Shen,Carson Balen,Albert Nguyen,Josh Tseng,Weng Si Leong,Michelle Liu,Pawel Lis,Santiago M Di Pietro,Annie Hiniker

Human molecular genetics 32:2808-2821 PubMed37384414

2023

Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson's disease models.

Applications

Unspecified application

Species

Unspecified reactive species

Matthew G Williamson,Marta Madureira,William McGuinness,Rachel Heon-Roberts,Elliot D Mock,Kalina Naidoo,Kaitlyn M L Cramb,Maria-Claudia Caiazza,Ana B Malpartida,Martha Lavelle,Katrina Savory,Stewart W Humble,Ryan Patterson,John B Davis,Natalie Connor-Robson,Brent J Ryan,Richard Wade-Martins

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8]

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (AB203181)

Related conjugates and formulations (2)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (61)

Product promise